Dr. Reddy’s Laboratories

Product promotions have also been barred. Nimish Mehta from Edelweiss confirms that “this could severely impact both sales and margins of Betapharm.” Prasad did admit that the expectations of the company from Deutschland could be fulfilled only in the long run. With several drugs going off patent in the next few years, governments across the world are expected to adopt stringent measures to control the prices of generics. France and Spain have already done it earlier this year. In the light of these latest developments, Dr. Reddy’s will increasingly feel the need to exercise extra caution with respect to all their future acquisitions overseas. They would certainly not want to get caught on the backfoot by policy changes on drug pricing the way they are facing in the land of the black forest.

For Complete IIPM - Article, Click on IIPM-Editorial Link

Source:- IIPM-Business and Economy, Editor:- Prof. Arindam Chaudhuri - 2006